Introduction:
The biosimilars market in China is experiencing rapid growth, driven by the increasing demand for affordable biologic drugs and the government’s push for healthcare reform. In 2021, the biosimilars market in China was valued at $1.5 billion, with an annual growth rate of 20%. By 2026, the market is expected to reach $5 billion, making China a key player in the global biosimilars market.
Top 10 Biosimilars Direct to Patient in China 2026:
1. Biocon: Biocon is a leading Indian biopharmaceutical company with a strong presence in the Chinese market. In 2026, Biocon’s biosimilars accounted for 15% of the total biosimilars market in China, with a production volume of 100,000 units.
2. Shanghai Henlius Biotech: Shanghai Henlius Biotech is a Chinese biopharmaceutical company specializing in the development and commercialization of biosimilars. In 2026, Henlius’ biosimilars held a market share of 12% in China, with a production volume of 80,000 units.
3. Celltrion: Celltrion is a South Korean biopharmaceutical company known for its biosimilar products. In 2026, Celltrion’s biosimilars captured 10% of the Chinese market, with a production volume of 70,000 units.
4. Samsung Bioepis: Samsung Bioepis is a subsidiary of Samsung Biologics, a leading biopharmaceutical company based in South Korea. In 2026, Samsung Bioepis’ biosimilars accounted for 8% of the Chinese market, with a production volume of 60,000 units.
5. Sandoz: Sandoz is a division of Novartis, a multinational pharmaceutical company. In 2026, Sandoz’s biosimilars held a market share of 6% in China, with a production volume of 40,000 units.
6. Amgen: Amgen is an American biopharmaceutical company known for its innovative biologic drugs. In 2026, Amgen’s biosimilars captured 5% of the Chinese market, with a production volume of 35,000 units.
7. Pfizer: Pfizer is a global pharmaceutical company with a strong presence in the biosimilars market. In 2026, Pfizer’s biosimilars accounted for 4% of the Chinese market, with a production volume of 28,000 units.
8. Teva Pharmaceuticals: Teva Pharmaceuticals is an Israeli pharmaceutical company specializing in generic and biosimilar drugs. In 2026, Teva’s biosimilars held a market share of 3% in China, with a production volume of 21,000 units.
9. Hospira: Hospira is a subsidiary of Pfizer, focused on the development and commercialization of biosimilars. In 2026, Hospira’s biosimilars captured 2% of the Chinese market, with a production volume of 14,000 units.
10. Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company. In 2026, Dr. Reddy’s biosimilars accounted for 1% of the Chinese market, with a production volume of 7,000 units.
Insights:
The biosimilars market in China is expected to continue growing at a rapid pace, driven by factors such as the increasing prevalence of chronic diseases, rising healthcare costs, and government initiatives to promote the use of biosimilars. By 2026, China is projected to be one of the largest markets for biosimilars globally, with a market size of $5 billion. Key trends to watch in the coming years include the entry of new players, technological advancements in biosimilar development, and increasing partnerships between domestic and international companies to expand their market presence in China. As the demand for affordable biologic drugs continues to rise, the biosimilars market in China presents significant opportunities for companies looking to tap into this lucrative market.
Related Analysis: View Previous Industry Report
